Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Long-Term Deferred Tax (2020 - 2023)

Universe Pharmaceuticals' Long-Term Deferred Tax history spans 4 years, with the latest figure at $599078.0 for Q3 2023.

  • On a quarterly basis, Long-Term Deferred Tax fell 55.55% to $599078.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $599078.0, a 55.55% decrease, with the full-year FY2023 number at $599078.0, down 55.55% from a year prior.
  • Long-Term Deferred Tax hit $599078.0 in Q3 2023 for Universe Pharmaceuticals, down from $830259.0 in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for UPC hit a ceiling of $186.5 billion in Q3 2020 and a floor of $599078.0 in Q3 2023.
  • Historically, Long-Term Deferred Tax has averaged $31.1 billion across 4 years, with a median of $927979.0 in 2021.
  • Biggest five-year swings in Long-Term Deferred Tax: plummeted 100.0% in 2021 and later surged 54.91% in 2022.
  • Tracing UPC's Long-Term Deferred Tax over 4 years: stood at $186.5 billion in 2020, then plummeted by 100.0% to $869997.0 in 2021, then surged by 54.91% to $1.3 million in 2022, then crashed by 55.55% to $599078.0 in 2023.
  • Business Quant data shows Long-Term Deferred Tax for UPC at $599078.0 in Q3 2023, $830259.0 in Q1 2023, and $1.3 million in Q3 2022.